LIGAND PHARMACEUTICALS INC (LGND)
SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026
Other listed symbols of this issuer: LGNDZ, LGNXZ, LGNYZ, LGNZZ
as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗
In its 10-Q for the period ended Jun 30, 2026, LIGAND PHARMACEUTICALS INC reported revenue of $63.7M, net income of $48.5M, and total assets of $2.19B. Every figure below is taken directly from LIGAND PHARMACEUTICALS INC's SEC filings: each links to the source document on EDGAR.
Revenue trend
Revenue · FY2016–FY2025 · as reported
- FY2016 revenue
- $109.0M
- FY2025 revenue
- $268.1M
Revenue and net income by fiscal year
As reported in each year’s annual filing · USD
| Fiscal year | Revenue | Net income |
|---|---|---|
| FY2025 | $268.1M | $124.5M |
| FY2024 | $167.1M | -$4.0M |
| FY2023 | $131.3M | $52.2M |
| FY2022 | $196.2M | -$33.4M |
| FY2021 | $241.5M | $57.1M |
| FY2020 | $163.6M | -$3.0M |
| FY2019 | $120.3M | $629.3M |
| FY2018 | $251.5M | $143.3M |
| FY2017 | $141.1M | $12.6M |
| FY2016 | $109.0M | -$1.6M |
Recent SEC filings
Filed by the registrant · newest first · insider forms and holder schedules not included
| Form | Filed | Source |
|---|---|---|
| 8-K | Oct 29, 2026 | on EDGAR ↗ |
| 8-K | Sep 24, 2026 | on EDGAR ↗ |
| 8-K | Sep 22, 2026 | on EDGAR ↗ |
| 10-Q | Aug 7, 2026 | on EDGAR ↗ |
| 8-K | Aug 6, 2026 | on EDGAR ↗ |
| 8-K | Jul 14, 2026 | on EDGAR ↗ |
| 8-K | Jun 25, 2026 | on EDGAR ↗ |
| 8-K | Jun 22, 2026 | on EDGAR ↗ |
| 8-K | Jun 9, 2026 | on EDGAR ↗ |
| 8-K | May 18, 2026 | on EDGAR ↗ |
Balance Sheet
as of Jun 30, 2026 · 10-Q
Income Statement
10-Q (quarterly) · period ended Jun 30, 2026
Per Share & Cash Flow
10-Q (quarterly) · period ended Jun 30, 2026
| EPS (diluted) | $2.22 | Earnings | source ↗ |
| EPS (basic) | $2.42 | Earnings | source ↗ |
| Shares Outstanding | 19.9M | Entity | source ↗ |
| Cash from Operations | $24.0M | Net | source ↗ |
| Cash from Financing | $546.4M | Net | source ↗ |
| Cash from Investing | $321.1M | Net | source ↗ |
Insider activity
Form 4 open-market activity, last 180 days
- Buys
- 0
- Sells
- 50
- Net shares
- -85.2K
Restatement history
Point-in-time54 of 516 annual fact-keys were materially restated between filings: what LIGAND PHARMACEUTICALS INC first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.
See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.
Deeper fundamentals
A free API key reaches LGND’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.
Programmatic access
Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.
- These fundamentals, as filed
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/LGND
MCP tool:
get_sec_fundamentals ticker=LGND - The same figures as they were known on any past date
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/LGND/as-of/YYYY-MM-DD
MCP tool:
get_asof_fundamentals ticker=LGND as_of=YYYY-MM-DD - Fiscal-year trajectory: revenue, margins, free cash flow
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/LGND/history
MCP tool:
get_fundamentals_history ticker=LGND - Leverage, liquidity, margin and return ratios
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/financial-health/LGND
MCP tool:
get_financial_health ticker=LGND
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.